Published in Cancer Weekly, March 8th, 1999
The study is designed to assess the drug's safety and efficacy in prolonging survival, and is conducted at 15 sites around the country. The study involves approximately 80 patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.